Ovarian Cancer Coverage from Every Angle

ASCO20 Preview: Survival Benefit Reported With Maintenance Olaparib in Advanced Ovarian Cancer

By: Lauren Harrison, MS
Posted: Friday, May 15, 2020

Maintenance treatment of patients with platinum-sensitive, relapsed ovarian cancer associated with BRCA1/2 mutations using the PARP inhibitor olaparib led to an extended overall survival by an “unprecedented 12.9 months” compared with placebo, based on the final analysis of the phase III SOLO2/ENGOT-ov211 trial. Andres Poveda, MD, of Initia Oncology, Hospital Quirónsalud, Valencia, Spain, presented these findings on behalf of colleagues at a press briefing prior to the ASCO20 Virtual Scientific Program (Abstract 6002).

The randomized, double-blind clinical trial recruited 295 patients who had platinum-sensitive recurrent ovarian cancer and a BRCA mutation. These patients had received at least two prior lines of chemotherapy; they were either in response to their most recent chemotherapy regimen or had no evidence of disease nor a rising CA-125 level. Patients were stratified into two groups based on their response to previous chemotherapy as well as length of platinum-free interval. Patients were administered 300-mg tablets of olaparib or placebo twice daily as maintenance therapy within 8 weeks of their last dose of chemotherapy.

At the time of final data cutoff, the median follow-up for both treatment groups was 65 months. There was a long-term treatment benefit seen with olaparib versus placebo, with overall survival times of 51.7 months compared with 38.8 months, respectively (hazard ratio = 0.74, P = .0537). A similar effect was seen patients with germline BRCA mutations. For this subset, the median overall survival was 52.4 months with olaparib compared with 37.4 months with placebo (hazard ratio = 0.71, P = .0306).

At 5 years, Kaplan-Meier estimates suggest that 28.3% of patients in the olaparib arm and 12.8% of patients in the placebo arm were alive and had not received subsequent treatment. In total, 42.1% of patients receiving olaparib and 33.2% of patients receiving the placebo were alive. The long-term tolerability of olaparib was consistent with previous reports.

Disclosure: For full authors’ disclosures, visit coi.asco.org.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.